Beijing Continent Pharmaceutical Co, Ltd. clinical trials
Acquired by GNI Group Ltd.
The registry lists 26 studies whose lead sponsor is Beijing Continent Pharmaceutical Co, Ltd.. 7 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 21, 2026.
Where
- China
- 25
Registry sponsor names on this page
- Beijing Continent Pharmaceutical Co, Ltd.26 studies
Something wrong with this grouping? Tell us on the GNI Group Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 26 of 26. All GNI Group Ltd. studies →
- A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal InsufficiencyRecruitingNCT07262333Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune PneumoniaRecruitingNCT07388680Phase 2/3
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Preliminary Human Trials of F230 TabletsRecruitingNCT06899815Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.Not yet recruitingNCT07412236Phase 3
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Efficacy and Safety of Pirfenidone Capsules in the Treatment of PneumoconiosisRecruitingNCT05288179Phase 3
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- F573 for Injection for the Treatment of Liver Injury/FailureRecruitingNCT05689645Phase 2
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver FibrosisRecruitingNCT05905172Phase 3
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- The Phase Ⅰd Clinical Trial of Hydronidone CapsulesCompletedNCT07262346Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- [¹⁴C] Hydronidone Mass Balance StudyCompletedNCT07471217Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir AmibufenamideCompletedNCT07295873Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy ControlsCompletedNCT07394309Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver CirrhosisCompletedNCT07343778Phase 3
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- QTc Assessment in a Single-Dose Study of Hydronidone CapsulesCompletedNCT07263152Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver FibrosisCompletedNCT07417553Phase 2
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver FibrosisCompletedNCT07364448Phase 2
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- A Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury.CompletedNCT03902509Phase 2
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.CompletedNCT05115942Phase 3
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- F573 Ia Clinical TrialCompletedNCT04820049Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Pirfenidone Capsule in Patients With Chronic Kidney Disease G2 and G3a Study on Safety and PharmacokineticsStatus unknownNCT04126538Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Study on PK of Hydronidone in Patients and Special PopulationCompletedNCT04123769Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Study on Pharmacokinetics of HydronidoneCompletedNCT04162821Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Study on Hydronidone Capsule BECompletedNCT04125056Not applicable
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Pharmacokinetic Interactions Between Hydronidone and Entecavir Capsules in Healthy Chinese SubjectsCompletedNCT04124081Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD)Status unknownNCT03857854Phase 3
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung DiseaseStatus unknownNCT03856853Phase 3
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung InjuryStatus unknownNCT02296281Phase 2
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group